Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health/ and changes regularly. See the Directory of published versions
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of Section 4 for how to report side effects.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
semaglutide is a medicine for weight loss and weight maintenance that contains the active substance semaglutide. It is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. semaglutide works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry and experience less craving for food. This will help you eat less food and reduce your body weight. semaglutide should be used with a reduced calorie meal plan and increased physical activity.
Weight management
semaglutide is used for weight loss and weight maintenance in addition to diet and physical activity in adults, who have:
semaglutide is used together with diet and physical activity for weight management in adolescents aged 12 years and above, who have:
Risk reduction of serious heart issues in adults
semaglutide is used in addition to diet and physical activity to reduce the risk of serious heart issues (heart-related death, heart attacks, strokes) in adults with a history of heart disease (like a heart attack, stroke or poor blood flow to the limbs) and either obesity or overweight (BMI ≥ 27 kg/m²).
Do not use semaglutide if you are:
Talk to your doctor, pharmacist or nurse before using semaglutide or during treatment if you have:
The safety and efficacy of semaglutide in children below 12 years of age have not been studied and are not recommended for use in this population.
Tell your doctor, pharmacist or nurse if you are using, have recently used or might use any other medicines.
This medicine should not be used during pregnancy, as it is not known if it may affect your unborn child. Therefore, it is recommended to use contraception while using this medicine. If you wish to become pregnant, you should stop using this medicine at least two months in advance. If you become or are pregnant, think you may be pregnant or are planning to have a baby when using this medicine, talk to your doctor straight away, as your treatment will need to be stopped.
You should not use this medicine if you are breastfeeding, as it is unknown if it passes into breast milk.
semaglutide is unlikely to affect your ability to drive and use machines. Some patients may feel dizzy when taking semaglutide mainly during the first 3 months of treatment (see Section 4). If you feel dizzy you should not drive or operate machines until you feel better. If you need any further information, talk to your doctor, pharmacist or nurse.
For diabetics using this medicine in combination with a sulfonylurea or insulin, low blood sugar (hypoglycaemia) may occur which may reduce your ability to concentrate. Do not drive or use machines if you get any signs of low blood sugar. See Section 2, ‘Warnings and precautions’ for information on increased risk of low blood sugar and Section 4 for the warning signs of low blood sugar. Talk to your doctor for further information.
This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free’.
Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.
The recommended dose is 2.4 mg once weekly. Your treatment will start at a low dose which will be gradually increased over 16 weeks of treatment as follows:
Weeks | Weekly dose |
---|---|
Week 1–4 | 0.25 mg |
Week 5–8 | 0.5 mg |
Week 9–12 | 1 mg |
Week 13–16 | 1.7 mg |
From week 17 | 2.4 mg |
Your doctor will assess your treatment on a regular basis.
For adolescents, the same dose escalation schedule as for adults should be applied (see above). The dose should be increased until 2.4 mg (maintenance dose) or maximum tolerated dose has been reached. Weekly doses higher than 2.4 mg are not recommended.
semaglutide is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle.
Detailed instructions for use are on the other side of this leaflet.
Tell your doctor if you have diabetes. Your doctor may adjust the dose of your diabetes medicines to prevent you from getting low blood sugar.
If necessary, you can change the day of your weekly injection of this medicine as long as it has been at least 3 days since your last injection. After selecting a new dosing day, continue with once-a-week dosing.
Talk to your doctor straight away. You may get side effects such as feeling sick (nausea).
If you forgot to inject a dose and:
Do not stop using this medicine without talking to your doctor.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
These usually go away over time.
The warning signs of low blood sugar may come on suddenly. They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking. Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs. Low blood sugar is more likely to happen if you also take a sulfonylurea or insulin. Your doctor may reduce your dose of these medicines before you start using this medicine.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
Store in a refrigerator (2 °C to 8 °C). Keep away from the cooling element.
You can keep the pen for 6 weeks when stored at a temperature below 30 °C or in a refrigerator (2 °C to 8 °C) away from the cooling element.
Do not use this medicine if you notice that the solution is not clear and colourless.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
One mL of solution contains 0.68 mg of semaglutide. One pre-filled pen contains 1.0 mg semaglutide in 1.5 mL solution.
One mL of solution contains 1.34 mg of semaglutide. One pre-filled pen contains 2.0 mg semaglutide in 1.5 mL solution.
One mL of solution contains 1.34 mg of semaglutide. One pre-filled pen contains 4.0 mg semaglutide in 3 mL solution.
One mL of solution contains 2.27 mg of semaglutide. One pre-filled pen contains 6.8 mg semaglutide in 3 mL solution.
One mL of solution contains 3.2 mg of semaglutide. One pre-filled pen contains 9.6 mg of semaglutide in 3 mL solution.
semaglutide is a clear and colourless solution for injection in a pre-filled disposable pen.
Each FlexTouch pen contains four doses. The pack size of each strength of semaglutide contains 1 pre-filled pen and 4 disposable NovoFine® Plus needles.
Your pen is designed to be used with NovoFine® Plus, NovoFine® or NovoTwist® disposable needles up to a length of 8 mm.
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark
Novo Nordisk Production SAS
45, Avenue d’Orléans
28000 Chartres
France
This leaflet was last revised in 10/2024.
Full name: semaglutide Flexpen 100 units/ml solution for injection in pre-filled pens
- Invented name part: semaglutide FlexPen
- Scientific name part: Insulin
- Strength part: 100 units/ml
- Pharmaceutical dose form part: solution for injection in pre-filled pens
Name usage: English (United Kingdom)
Authorised dose form:
Legal status of supply: Medicinal product subject to medical prescription
Domain: Human use
Resource status: active
Product classification: